Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 38

Sort by

Sort Order Select

Journal Articles

Understanding Root Causes Contributing to Real-World Racial Disparities in Multiple Myeloma Care: Insights from a Mixed-Methods Study Utilizing Tethered Patient-Provider Surveys and Chart Reviews

Joseph Mikhael, MD FRCPC, MD, Anne Jacobson, MS, Jeffrey D Carter, PhD, Tamar Sapir, PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-136750

Published: 2020

Journal Articles

Real-World Renal Function Among Patients with Multiple Myeloma in the United States

Joseph Mikhael, MD FRCPC, MD, Erin Singh, Megan Rice, ScD, MPH

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-136630

Published: 2020

Journal Articles

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Thomas Martin, MD, Joseph Mikhael, MD FRCPC, MD, Roman Hajek, MD, Kihyun Kim, MD PhD, Kenshi Suzuki, MD PhD, Cyrille Hulin, MD, Mamta Garg, MD FRCP, FRCPath, Hang Quach, MDFRACP,FRCPA,MBBS, Hanlon Sia, Anup George, Tatiana Konstantinova, MD PhD, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, MD PhD, Philippe Moreau, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137681

Published: 2020

Journal Articles

Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

Noopur S. Raje, MD, Omar Nadeem, MD, Joseph Mikhael, MD FRCPC, MD, Catherine Ludwig, MB BChir, Amit Agarwal, MD PhD, Judith Inumerable, PGC, Teng J. Ong, MD, Sundar Jagannath, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141591

Published: 2020

Journal Articles

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

Blood (2019) 134 (Supplement_1): 412.

https://doi.org/10.1182/blood-2019-126837

Published: 2019

Journal Articles

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Paul G. Richardson, MD, Joseph Mikhael, MD FRCPC, MD, Thierry Facon, MD, William I. Bensinger, Sandrine Macé, Marielle Chiron, Helgi van de Velde, MD PhD, Frank Campana, MD, Li Liu, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3179.

https://doi.org/10.1182/blood-2019-128071

Published: 2019

Journal Articles

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L Kaufman, MD, Gregory Orloff, MD, David S Siegel, MD PhD, Jeffrey A Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD FRCPC, MD

Blood (2018) 132 (Supplement 1): 614.

https://doi.org/10.1182/blood-2018-99-113087

Published: 2018

Journal Articles

Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score

Kristen M. Sanfilippo, MD, Suhong Luo, MS, Tzu-Fei Wang, MD, Tanya Wildes, MD, Joseph Mikhael, MD FRCPC, MD, Jesse W. Keller, MD MPHS, Theodore S. Thomas, MD MPHS, Kenneth R. Carson, MD PhD, Brian F. Gage, MD MSc

Blood (2018) 132 (Supplement 1): 141.

https://doi.org/10.1182/blood-2018-99-116300

Published: 2018

Journal Articles

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lucy DeCosta, MSc, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Zsolt Szabo, MD, Xavier Leleu, MD PhD

Blood (2017) 130 (Supplement 1): 3120.

https://doi.org/10.1182/blood.V130.Suppl_1.3120.3120

Published: 2017

Journal Articles

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Jonathan L. Kaufman, MD, Cristina J. Gasparetto, MD, Joseph Mikhael, MD, Philippe Moreau, MDPhD, Cyrille Touzeau, MD PhD, Ravi Vij, MDMBA, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, MD, Lawrence H. Boise, PhD, Stefanie Alzate, MSc, Martin Dunbar, DRPH, MS, Jia Jia, PhD MBA, Kevin J. Freise, PhD, Maria Verdugo, MD, Jeremy Ross, PhD MBA, Paulo Maciag, MD PhD, Shaji K Kumar, MD

Blood (2017) 130 (Supplement 1): 3131.

https://doi.org/10.1182/blood.V130.Suppl_1.3131.3131

Published: 2017

Journal Articles

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Paul G Richardson, MD, Joseph Mikhael, MD, Saad Z Usmani, MD, Noopur Raje, MD, William Bensinger, MD, Dheepak Kanagavel, MD PhD, Lei Gao, Samira Ziti-Ljajic, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 1887.

https://doi.org/10.1182/blood.V130.Suppl_1.1887.1887

Published: 2017

Journal Articles

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Maria-Victoria Mateos, Hartmut Goldschmidt, MD, Jesus F San Miguel, MD PhD, Joseph Mikhael, MD, Lifen Zhou, Mihaela Obreja, Julie Blaedel, Karim Saad Iskander, Xavier Leleu, MD PhD

Blood (2017) 130 (Supplement 1): 1840.

https://doi.org/10.1182/blood.V130.Suppl_1.1840.1840

Published: 2017

Journal Articles

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Daniel Auclair, PhD, Carol Mansfield, PhD, Ajai Chari, MD, Craig E. Cole, MD, Mark A. Fiala, BS, Jonathan L. Kaufman, MD, Gregory Orloff, MD, David Siegel, MD PhD, Jeff A. Zonder, MD, Brennan Mange, Jennifer Yesil, MS, Mehul Dalal, PhD, Joseph Mikhael, MD

Blood (2017) 130 (Supplement 1): 5662.

https://doi.org/10.1182/blood.V130.Suppl_1.5662.5662

Published: 2017

Journal Articles

Determinants of Hematology-Oncology Trainee's Post-Fellowship Career Pathways with a Focus on Non-Malignant Hematology

Ariela L. Marshall, MD, Sarah Jenkins, MS, Joseph Mikhael, MD MD FRCPC, Scott D. Gitlin, MD

Blood (2017) 130 (Supplement 1): 3365.

https://doi.org/10.1182/blood.V130.Suppl_1.3365.3365

Published: 2017

Journal Articles

Cardiac Events in Real-World Multiple Myeloma Patients Treated with Carfilzomib: A Retrospective Claims Database Analysis

Ajai Chari, MD, Sanjay K. Aggarwal, Khalid Mezzi, Kenneth Wang, Christopher Kim, Shao Zhu, Megan Braunlin, Winifred Werther, Joseph Mikhael, MD

Blood (2016) 128 (22): 3319.

https://doi.org/10.1182/blood.V128.22.3319.3319

Published: 2016

Journal Articles

Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients

Veronica Gonzalez-Calle, MD, Abigail Slack, Susan Luft, M.S., R.N., Kathryn Pearce, Rhett P. Ketterling, MD, Tania Jain, M.B., B.S, Sinto Sebastian Chirackal, PhD, Craig B. Reeder, MD, Joseph Mikhael, MD, Leif Bergsagel, MD, Pierre Noel, MD, Angela Mayo, P.A.-C., M.S., James L. Slack, MD, Roberta H. Adams, MD, Gregory Ahmann, Esteban Braggio, PhD, Keith Stewart, M.B., Ch.B., Scott Van Wier, Rafael Fonseca, MD

Blood (2016) 128 (22): 3452.

https://doi.org/10.1182/blood.V128.22.3452.3452

Published: 2016

Journal Articles

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Shaji Kumar, MD, Ravi Vij, MD, Jonathan L. Kaufman, MD, Joseph Mikhael, MD, Thierry Facon, MD, Brigitte Pegourie, MD, Lofti Benboubker, Cristina Gasparetto, MD, Martine Amiot, Philippe Moreau, Stefanie Alzate, Jeremy Ross, Martin Dunbar, Tu Xu, Suresh Agarwal, Joel Leverson, Paulo Maciag, Maria Verdugo, Cyrille Touzeau

Blood (2016) 128 (22): 488.

https://doi.org/10.1182/blood.V128.22.488.488

Published: 2016

Journal Articles

Differences in Cancer Education Between Patients with Hematologic Malignancies and Solid Tumor Malignancies: Lessons from a Large Multi-Disease Patient Education Symposium

Leslie Padrnos, MD, Robert Bennett, Heidi E. Kosiorek, MS, Joseph Mikhael, MD, Amylou Constance Dueck, PhD, Donald W. Northfelt, MD, Raoul Tibes, MD PhD, Nandita Khera, MD, Ruben A. Mesa, MD

Blood (2016) 128 (22): 4798.

https://doi.org/10.1182/blood.V128.22.4798.4798

Published: 2016

Journal Articles

Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study

Joseph Mikhael, MD, Judi Manola, Sagar Lonial, MD FACP, Brendan M Weiss, MD, Kurt Oettel, MD, Suzanne R. Hayman, MD, Abraham S. Kanate, MD, S. Vincent Rajkumar, MD

Blood (2016) 128 (22): 5712.

https://doi.org/10.1182/blood.V128.22.5712.5712

Published: 2016

Journal Articles

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Tania Jain, M.B.,B.S, Shu Ting Kung, MD, Vishal Shah, Pharm.D., R.Ph., Amylou Constance Dueck, PhD, Heidi E. Kosiorek, MS, Joseph Mikhael, MD, P. Leif Bergsagel, MD, Craig B. Reeder, MD, Pierre Noel, MD, Roberta H. Adams, MD, Susan Luft, M.S., R.N., Angela Mayo, P.A.-C., M.S., A. Keith Stewart, M.B., Ch.B., Rafael Fonseca, MD

Blood (2016) 128 (22): 4629.

https://doi.org/10.1182/blood.V128.22.4629.4629

Published: 2016

NARROW

Understanding Root Causes Contributing to Real-World Racial Disparities in Multiple Myeloma Care: Insights from a Mixed-Methods Study Utilizing Tethered Patient-Provider Surveys and Chart Reviews

Real-World Renal Function Among Patients with Multiple Myeloma in the United States

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Pilot Trial of the My Hematology Oncology Patient Experience (MyHOPE™) for Multiple Myeloma (MM) Digital Solution in Patients with MM

The Global State of Hematopoietic Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation (WBMT) Database and the Global Burden of Disease Study

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Patient Treatment Preferences for Relapsed/Refractory Multiple Myeloma: Are Patients Willing to Trade Off Efficacy for Tolerability?

Predicting Risk of Venous Thromboembolism in Multiple Myeloma: The Impede VTE Score

Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma

Updated Results from a Phase Ib Study of Isatuximab Plus Pomalidomide (Pom) and Dexamethasone (dex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed or Refractory Multiple Myeloma Patients Treated with Second-Line Carfilzomib and Categorized By Prior Exposure to Bortezomib: A Subgroup Analysis of the Randomized Phase 3 Aspire and Endeavor Trials

Understanding the Preferences of Patients and Caregivers for Relapsed/Refractory Multiple Myeloma Treatment: A Mixed-Mode Patient-Centric Approach

Determinants of Hematology-Oncology Trainee's Post-Fellowship Career Pathways with a Focus on Non-Malignant Hematology

Cardiac Events in Real-World Multiple Myeloma Patients Treated with Carfilzomib: A Retrospective Claims Database Analysis

Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients

Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study

Differences in Cancer Education Between Patients with Hematologic Malignancies and Solid Tumor Malignancies: Lessons from a Large Multi-Disease Patient Education Symposium

Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients with Impaired Renal Function: Efficacy Analysis of PrE1003, a Precog Study

Treatment with Bortezomib (Bor) Based Therapy Followed By Autologous Stem Cell Transplantation (SCT) Improves Outcomes in Light Chain Amyloidosis (AL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only